HD-OPM Archive

LDL and ApoB explained: the cause of plaque and how low to go

LDL cholesterol and ApoB are the main causal drivers of atherosclerotic plaque, and ApoB (a count of atherogenic particles) is the more accurate way to measure them. This summary explains the evidence, the targets the group's sources cite, and where "lower is better" has limits.

14 min read58 group posts cited32 studies discussed2 chartsEvidence through Oct 2026AI Summary of posts by Louis Nervegna and Gokhan Can
Key takeaways
  • ApoB counts the atherogenic particles in your blood (LDL, VLDL, Lp(a) and others) while LDL-C measures only the cholesterol inside LDL; the group's admins favor ApoB because particle number predicts risk better than cholesterol content.
  • In the Copenhagen General Population Study of 13,015 statin users, high ApoB with normal LDL-C carried a 49% higher heart attack rate, while high LDL-C with normal ApoB showed no excess risk.
  • Genetics, randomized trials and mechanism all point the same way. In EZ-PAVE (over 3,000 patients), an LDL goal under 55 mg/dL cut major events by 33% compared with under 70 mg/dL, with 6.6% versus 9.7% over 3 years.
  • Guideline LDL-C goals scale with risk: under 100 mg/dL for borderline or intermediate risk, under 70 for high risk and under 55 for very high-risk secondary prevention, per the 2026 ACC/AHA summary Louis shared.
  • Lower is better has caveats: benefit depends on both how low and how long, residual risk persists in every trial, and Louis argues for proportionality rather than driving everyone to very low levels.
  • LDL particle size adds no risk information once particle number or ApoB is known, and very high LDL on a ketogenic diet did not protect against plaque in the Keto-CTA study.
In this summary
  1. LDL-C, LDL-P and ApoB: what each test actually measures
  2. Why LDL and ApoB are considered causal
  3. What targets do the sources cite?
  4. Is lower always better?
  5. What this means for you
  6. Frequently asked questions
  7. The evidence behind this summary

LDL cholesterol is often called "bad cholesterol", but the more precise story is about particles. Cholesterol travels in the blood inside lipoprotein particles, and the ones that wear a protein tag called apolipoprotein B (ApoB) are the ones that can enter the artery wall and be retained there, where they drive plaque. LDL is the most numerous of these, but VLDL (the main carrier of triglycerides), Lp(a) and a few others carry the same tag.12

The group's position, argued mainly by Louis Nervegna and Gokhan Can, is that LDL and ApoB are causal, meaning they are not just markers but actual drivers of atherosclerosis, and that the best way to measure them is ApoB. The evidence cited for causality comes from genetics, randomized trials and biology. How low to go, though, is less settled: targets scale with risk, benefit depends on duration as well as depth, and the admins themselves attach several cautions to "lower is always better".34

This article walks through what the numbers mean, why the evidence supports causality, which targets are cited, and where the nuances are.

49%higher heart attack rate on statins when ApoB was high but LDL-C normal (Copenhagen, 13,015 people)5
33%fewer major events with an LDL goal under 55 versus under 70 mg/dL (EZ-PAVE)6
30%higher risk of heart attack or stroke after 40 with more atherogenic particles at ages 18 to 40 (CARDIA)7
~$28for an ApoB test ordered yourself8

LDL-C, LDL-P and ApoB: what each test actually measures

Louis explains the difference like this9:

  • LDL-C is the amount of cholesterol carried inside all LDL particles. It is what most standard lab reports mean by "LDL".
  • LDL-P is the number of LDL particles.
  • ApoB is the number of all ApoB-tagged particles, of which LDL-P is a subset. It also counts VLDL and other atherogenic particles.

The two can disagree. Someone can have a low LDL-C but a high particle count if their particles are small and each carries little cholesterol. Louis argues that such "discordant" people may be at higher risk than their LDL-C suggests, because the number of atherogenic particles predicts risk better than the cholesterol mass.912 He also notes that in most people the markers move together, and a significant discordance is uncommon but can happen.13

A boats-and-cargo picture

Louis uses an analogy: lipoprotein particles are boats, cholesterol and triglyceride are the cargo, and ApoB is a sign on the boat marking it as dangerous. LDL and Lp(a) boats carry LDL cholesterol, VLDL boats carry triglyceride, and an ApoB test counts all the boats with the sign.1

One consequence is that the LDL-C on a lab report includes cholesterol carried by Lp(a). In people with very high Lp(a), a significant share of reported LDL-C may come from Lp(a). Louis adds that Lp(a) appears especially dangerous because its apo(a) protein is sticky in the artery wall and is prothrombotic.1415

Triglycerides, VLDL and "double counting"

Triglycerides are mostly carried by VLDL, which is ApoB-tagged, so VLDL adds to total ApoB just as LDL does. Louis therefore finds it inconsistent to accept that Lp(a) and triglyceride-rich particles are causal while denying that LDL is.16 His practical point is that triglycerides below 400 mg/dL do still matter when carried by VLDL, but they are already counted in ApoB, so using both separately double counts risk.17

Louis also describes drug trials where lowering triglycerides did not shrink plaque. In BRIDGE-TIMI 73a, olezarsen cut triglycerides 64% without changing plaque volume. He says triglycerides mainly act as a proxy for metabolic health, with the atherogenic part captured by ApoB.18 He also notes that insulin resistance and LDL are independent risk factors, so both matter.1920

Particle size and the NMR test

Louis repeatedly argues that LDL particle size does not matter once particle number is counted. NMR reports themselves say that small LDL-P and LDL size are associated with CVD risk, "but not after LDL-P is taken into account". Having large, "fluffy" particles will not protect someone with a high ApoB.21222324 A 2025 European Heart Journal paper he shared concluded that lipid-related risk is best reflected by total ApoB particle count, largely independent of particle type or size, with elevated Lp(a) adding risk.25 Gokhan relays a genetic analysis in about 200,000 people over 14 years in which ApoB plus Lp(a) best captured lipid-mediated risk and size added nothing, and he advises against paying for NMR particle-size panels.26

A LabCorp NMR report: next to the particle-size ranges, the lab itself states that small LDL-P and LDL size "are associated with CVD risk, but not after LDL-P is taken into account".
A LabCorp NMR report: next to the particle-size ranges, the lab itself states that small LDL-P and LDL size "are associated with CVD risk, but not after LDL-P is taken into account".21

Can you estimate ApoB from a standard panel?

Technically no, but Louis says you can get a rough feel. Non-HDL cholesterol (total cholesterol minus HDL) is mostly LDL plus some VLDL and a little IDL, and he gives a crude estimate of ApoB at about 0.7 times non-HDL cholesterol.27 He also offers ApoB of roughly 0.7 x (LDL + triglycerides/5). The direct ApoB test is still more accurate because it counts particles, including some not captured by non-HDL.2728 He points out that ApoB tests are cheap, citing about $28 if ordered yourself.8

Why LDL and ApoB are considered causal

Genetics: lifelong exposure

Mendelian randomization uses gene variants that raise or lower a factor from birth as a natural experiment. A chart from a European Atherosclerosis Society consensus statement, explained by Louis, shows variants acting through different pathways (LDLR, PCSK9, APOB, HMGCR, NPC1L1 and others). In each case, coronary risk changes in proportion to the LDL change. Lifetime relative risk reductions range from about 5% to 90%, and the pattern is the same linear relationship seen in statin trials. He notes that a 90% reduction applied to an average American lifetime heart attack risk of about 20% would leave about 2%.29

The Mendelian randomization chart Louis explained: each dot is a gene variant (LDLR, PCSK9, HMGCR, NPC1L1 and others), plotting its change in LDL-C against its change in coronary heart disease risk; the points fall along one straight line.
The Mendelian randomization chart Louis explained: each dot is a gene variant (LDLR, PCSK9, HMGCR, NPC1L1 and others), plotting its change in LDL-C against its change in coronary heart disease risk; the points fall along one straight line.29

Gokhan also summarized a 2024 Mendelian randomization study (Martin et al.) in which each 1 SD genetically higher ApoB shortened healthspan, the time to first chronic disease, by about 0.13 years, with a direct effect independent of LDL.30

Randomized trials: lower LDL, fewer events and less plaque

Louis highlights EZ-PAVE, a NEJM trial of over 3,000 patients with established heart disease. Both arms were already treated: one targeted LDL below 70 mg/dL with a statin, the other below 55 with a statin plus ezetimibe. Major events over 3 years were 9.7% versus 6.6%, a 33% reduction, with essentially identical safety.6

Imaging studies tell a similar story. In a meta-analysis of 31 IVUS studies with 4,997 patients, lipid-lowering reduced total and percent atheroma volume, with maximal regression at LDL below 80 mg/dL, and each 1% fall in percent atheroma volume was linked to 20% lower event risk (an association).31 Louis also quotes a Medscape interview in which about half of subjects regressed at LDL near 80 and about 90% of regressable plaques regressed below 60.32

Particle number in outcomes

The Copenhagen General Population Study, summarized in a post Louis shared, followed 13,015 adults on statins for a median of 8 years. People with high ApoB but normal LDL-C had a 49% higher rate of heart attack and a 21% higher rate of death than people with both markers low, whereas high LDL-C with normal ApoB showed no excess risk. Non-HDL cholesterol behaved like ApoB.5 The CARDIA analysis he shared found that people with higher atherogenic particle counts between ages 18 and 40 had a 30% higher risk of heart attack or stroke after 40, with no safe lower threshold identified.7 A JACC Advances study of 1,033 "low-risk" adults found plaque in 35.9%, with prevalence rising with LDL, non-HDL and ApoB even below guideline levels.33

On statins, high ApoB tracked risk; high LDL-C alone did notCopenhagen General Population Study, 13,015 adults on statins, median 8 years: rate versus people with both markers low, when the two markers disagreed
High ApoB, normal LDL-C: heart attack+49%
High ApoB, normal LDL-C: death from any cause+21%
The mirror image, high LDL-C with normal ApoB, showed no excess risk of heart attack or death. Observational data from people already on statins. Source: 5
Show data
Value
High ApoB, normal LDL-C: heart attack+49%
High ApoB, normal LDL-C: death from any cause+21%

Mechanism

Gokhan explains that cholesterol itself is essential, but having too many ApoB particles means more of them enter the artery wall and are trapped there, driving an inflammatory, cholesterol-rich plaque.2 Louis adds that LDL oxidation that matters mostly happens inside the artery wall, after particles are retained. Oxidized LDL measured in blood does not predict risk once ApoB is accounted for, which is why Tom Dayspring calls the circulating test "useless".3435

What targets do the sources cite?

LDL-C goals by risk

Louis summarized the 2026 ACC/AHA lipid guideline: the goal is under 100 mg/dL for borderline or intermediate risk, under 70 for high risk, and under 55 for people with very high-risk ASCVD (secondary prevention). Any coronary calcium supports a goal under 100, with lower targets for higher calcium amounts.10 An earlier summary by Gokhan of a 2023 JAHA review gives similar thresholds, with at least a 50% LDL-C reduction for high and very high risk and a goal under 40 for recurrent events on statins in the very high-risk group.36 A separate Louis post lists expert targets of under 55 (very high risk), under 70 (high), under 100 (moderate) and under 116 (low).37

Risk group2026 ACC/AHA guideline102023 JAHA review36Expert targets list37
Very high riskunder 55 mg/dL (secondary prevention)under 55, or under 40 for recurrent events on statins; at least 50% reductionunder 55
High riskunder 70under 70; at least 50% reductionunder 70
Borderline, intermediate or moderate riskunder 100not givenunder 100
Low risknot givennot givenunder 116

The groupings differ slightly between sources, and the admins stress that these are not hard rules. Individual decisions should be made with a doctor.

ApoB goals

Gokhan summarized Gil Carvalho's video, which suggests ApoB ideally under 100 mg/dL for healthy people and under 80 for those at higher risk.38 The National Lipid Association consensus, as summarized in the group, says ApoB testing is most useful for borderline-risk patients deciding on a statin and for people considering treatment intensification, with ApoB thresholds matching LDL-C goals. It stresses that routine ApoB for everyone is not required.3940 The 2026 ACC/AHA summary says ApoB may be used to assess residual risk in people with cardiovascular-kidney-metabolic syndrome, type 2 diabetes, high triglycerides or known cardiovascular disease who have reached LDL-C goals.10

Examples from the group: Gokhan shared labs of LDL 61 and ApoB 58 mg/dL on 5 mg rosuvastatin.41 He has said he prefers an LDL of about 70 mg/dL within a 70 to 100 range as his own personal approach.4

How to get there

  • Statins. Louis, sharing a Dayspring slide, notes diminishing returns: atorvastatin 10 mg lowers LDL about 37%, 20 mg 43%, 40 mg 48% and 80 mg 51%. He suggests maximizing lifestyle first and then using the lowest effective dose, and lowering rather than stopping the dose if side effects occur.4243
  • Ezetimibe. Gokhan's summary gives an average LDL-C reduction of 18-20% alone and a further 21-30% on top of a statin.44
  • Fiber. A meta-analysis of 28 trials found about 10 g/day of psyllium lowered LDL by about 13 mg/dL. A meta-analysis of 74 trials found oats lowered LDL-C by 0.29 mmol/L.454647
  • Dietary fats. Louis notes that coconut oil raises LDL and ApoB, though less than butter. In a crossover trial, butter raised ApoB by 10 mg/dL while full-fat yogurt lowered it by 4.4849 Louis states that most saturated fats raise LDL-P, ApoB and LDL-C.13
Most of a statin's LDL lowering comes from the first dose stepAverage LDL reduction by atorvastatin dose, from a Tom Dayspring slide shared by Louis Nervegna
Atorvastatin 10 mg37%
Atorvastatin 20 mg43%
Atorvastatin 40 mg48%
Atorvastatin 80 mg51%
Doubling the dose adds 6, then 5, then 3 percentage points. Source: 42
Show data
Value
Atorvastatin 10 mg37%
Atorvastatin 20 mg43%
Atorvastatin 40 mg48%
Atorvastatin 80 mg51%

Is lower always better?

Duration matters as much as depth

Gokhan's "the longer the lower the better" post argues that benefit depends on both how much and how long LDL is lowered. He estimates about 60% lifetime risk reduction for a 70 mg/dL drop sustained for 30 years, based on reading a chart, and he notes that effects beyond about 80 mg/dL of lowering are unknown.4 The CARDIA finding, which tracks particle exposure across ages 18 to 40, fits this idea.7

Proportionality and possible downsides

Louis shared an NEJM review whose message is "proportionality, not 'lower for everyone'". Targets should scale with absolute risk, with a focus on lifestyle in lower-risk people.3 Louis also criticizes advice that low-risk people should use multiple drugs to push LDL-C below 20 mg/dL. He cites Walter Willett's view that very low LDL may increase hemorrhagic stroke risk, and he stresses this does not apply to high-risk people, for whom heart attack and ischemic stroke risk outweigh it.50 This is an opinion presented with evidence from one expert; the group's index also lists posts on whether low cholesterol is harmful.51

LDL is not a cure

Louis stresses that residual risk persists in every randomized trial, regardless of how low LDL goes, and that it appears higher in older people. Lowering ApoB is no cure. He lists other drivers such as family history, blood pressure, smoking, weight, inflammation, diet, inactivity and insulin resistance.11 Gokhan's index post gives a blunt rule: if you are at high risk, find a good cardiologist and listen to them.51

"My LDL is high but I'm metabolically healthy"

The Keto-CTA (LMHR) study is central to this debate. Louis says it tested whether good metabolic health and large LDL particles protect against very high LDL, with an average LDL of 254 mg/dL, and found no protection. He reports plaque progression of 3 to 3.8 times worse than a comparison group with normal LDL, while the DISCO intervention (statins, other medications and a DASH diet) achieved significant plaque reversal in a year.5253 Louis proposes that the LMHR phenotype reflects a starvation-like response in very lean people on strict keto.54 Not everyone is affected: a video Louis recommends says some people are genetically protected despite high LDL, but most are not.55

Annual change in non-calcified plaque volume across studies, as compared in a graph shared from the LMHR group: the Keto-CTA lean mass hyper-responders (LDL-C 237 mg/dL) show the largest growth, while the DISCO-CT intervention group shows the largest reversal. The Keto-CTA paper was later retracted, as the keto summary explains.
Annual change in non-calcified plaque volume across studies, as compared in a graph shared from the LMHR group: the Keto-CTA lean mass hyper-responders (LDL-C 237 mg/dL) show the largest growth, while the DISCO-CT intervention group shows the largest reversal. The Keto-CTA paper was later retracted, as the keto summary explains.52

HDL is another common distraction. Louis notes that HDL-raising drug trials failed on hard outcomes and treats HDL as a crude proxy for insulin resistance.56

What this means for you

  • Ask about ApoB. The group's admins favor it over LDL-C alone, especially if triglycerides are high, you have diabetes or metabolic syndrome, or your LDL-C looks low but you have other risk factors.939
  • Measure Lp(a) at least once. The 2026 guideline summary says to measure it at least once in adulthood, with high values (125 nmol/L or above) linked to about a 1.4-fold higher long-term risk.10 Gokhan's explainer says Lp(a) is 80-90% genetic and stable through life.57
  • Discuss the right target with your doctor. The sources cite under 100, 70 or 55 mg/dL for LDL-C depending on risk.610
  • Don't rely on particle size, oxidized LDL or HDL. The admins say particle size and circulating oxidized LDL add nothing once ApoB is known.2134
  • Think long term. Earlier and sustained lowering is argued to give more benefit.47
  • Combine approaches. Diet, fiber, the lowest effective statin dose and ezetimibe are all discussed. Louis suggests LDL lowering combined with attention to inflammation, insulin resistance and the aging process.324244

Frequently asked questions

Is LDL-C or ApoB the better test?

Louis argues ApoB is the best lipid test because it counts all atherogenic particles, with LDL-C usually tracking it. Standard panels also miss Lp(a), remnants and other ApoB-rich particles.1358

Can I calculate ApoB myself?

Only roughly. Louis gives about 0.7 x non-HDL cholesterol, or 0.7 x (LDL + TG/5), but recommends the direct test.2728

If my LDL-C is under 100, am I safe?

Not necessarily. The Copenhagen study found high ApoB with normal LDL-C carried higher risk, and residual risk persists in every trial.511

Do triglycerides matter?

Yes, as VLDL particles carrying ApoB. But Louis says they are already counted in ApoB, and lowering triglycerides alone with drugs did not shrink plaque in the olezarsen trial.1718

Can LDL be too low?

For most people at risk, the sources cited favor lower. Louis notes a possible hemorrhagic stroke concern at very low levels in low-risk people, and a proportionate approach in the NEJM review.350

The evidence behind this summary32 studies · 5 meta-analyses · 5 trials · 2 MR · 6 observational

The 58 group posts cited above discuss 32 studies and sources. Their mix of study designs shows how much rests on randomized trials and meta-analyses, which can show cause and effect, and how much on observational, lab or animal work, which mostly cannot.

Meta-analyses 5Randomized trials 5Mendelian randomization 2Observational studies 6Reviews & guidelines 8Other sources 6

Strongest evidence discussed

All 32 studies and sources
Sources from the group (58)
  1. ApoB is the 'sign' on atherogenic particles; LDL and Lp(a) carry LDL cholesterol Louis Nervegna · Jun 15, 2025 · Facebook
  2. Why elevated cholesterol harms: ApoB particles drive plaque and inflammatory aging Gokhan Can · Nov 09, 2025 · Facebook
  3. NEJM review: LDL targets should scale with absolute risk, not 'lower for everyone' Louis Nervegna · Feb 05, 2026 · Facebook
  4. The longer the lower the better: lifelong LDL lowering and an estimated 60% risk reduction Gokhan Can · Nov 20, 2023 · Facebook
  5. On statins, high ApoB with normal LDL-C raised MI risk 49%; high LDL-C alone did not Louis Nervegna · Jul 30, 2026 · Facebook
  6. EZ-PAVE: LDL target <55 vs <70 cut major CV events by 33% in over 3,000 patients Louis Nervegna · Mar 31, 2026 · Facebook
  7. CARDIA: high ApoB or LDL-P at ages 18-40 linked to 30% higher heart attack/stroke risk Louis Nervegna · Nov 04, 2025 · Facebook
  8. ApoB tests are cheap, about $28 if ordered yourself Louis Nervegna · Feb 22, 2024 · Facebook
  9. LDL-C vs LDL-P vs ApoB: particle number predicts risk better than cholesterol content Louis Nervegna · Jul 16, 2024 · Facebook
  10. 2026 ACC/AHA lipid guideline keeps LDL targets and adds Lp(a), apoB and CAC testing Louis Nervegna · Mar 13, 2026 · Facebook
  11. Lowering LDL or ApoB is no cure: residual risk persists in every trial; age matters most Louis Nervegna · Aug 20, 2024 · Facebook
  12. Video: why ApoB is a better CVD risk marker than LDL-C and what discordance means Louis Nervegna · Mar 09, 2024 · Facebook
  13. Fact-checking keto and carnivore influencer claims about LDL, ApoB and saturated fat Louis Nervegna · May 28, 2025 · Facebook
  14. Lp(a) carries LDL cholesterol, so LDL-C on a lab report includes Lp(a) cholesterol Louis Nervegna · Jun 14, 2025 · Facebook
  15. Lp(a) carries LDL cholesterol, so lab LDL-C includes cholesterol from Lp(a) particles Louis Nervegna · Oct 10, 2025 · Facebook
  16. Lp(a) and triglycerides are ApoB particles, so accepting them but not LDL is odd Louis Nervegna · Jul 21, 2024 · Facebook
  17. Triglycerides still matter below 400 mg/dL but are already counted in ApoB Louis Nervegna · Feb 17, 2025 · Facebook
  18. Lowering triglycerides alone does not shrink plaque: olezarsen cut TG 64%, plaque flat Louis Nervegna · May 20, 2026 · Facebook
  19. TG/HDL is a marker of insulin resistance, and triglycerides are also directly atherogenic Louis Nervegna · Jul 28, 2025 · Facebook
  20. Interview: insulin resistance and LDL/ApoB are both independent causes of heart disease Louis Nervegna · Feb 23, 2024 · Facebook
  21. LDL particle size does not predict CVD risk once particle number or ApoB is accounted for Louis Nervegna · Jan 22, 2025 · Facebook
  22. NMR reports state LDL particle size adds no risk information once LDL-P is accounted for Louis Nervegna · Jul 29, 2024 · Facebook
  23. NMR LDL particle size adds no risk information once LDL-P or ApoB is known Louis Nervegna · Apr 30, 2026 · Facebook
  24. NMR lipid reports state LDL size adds no risk information once LDL-P is known Louis Nervegna · Aug 17, 2025 · Facebook
  25. Eur Heart J 2025: apoB particle count, not size or type, drives coronary risk Louis Nervegna · Apr 30, 2025 · Facebook
  26. ApoB and Lp(a) capture lipid risk; LDL particle size adds nothing once apoB is known Gokhan Can · May 02, 2025 · Facebook
  27. ApoB cannot be calculated from a lipid panel but is roughly 0.7 times non-HDL cholesterol Louis Nervegna · Sep 02, 2025 · Facebook
  28. ApoB can be roughly estimated as 0.7 x (LDL + TG/5); non-HDL cholesterol approximates it Louis Nervegna · Apr 30, 2026 · Facebook
  29. Mendelian randomization: lifelong lower LDL tracks linearly with lower heart disease risk Louis Nervegna · Oct 10, 2026 · Facebook
  30. Mendelian randomization: higher ApoB shortens healthspan and may raise Alzheimer's risk Gokhan Can · Feb 25, 2024 · Facebook
  31. Meta-analysis: lipid-lowering therapy regresses coronary plaque (Li 2021, SATURN) Gokhan Can · Nov 25, 2023 · Facebook
  32. Plaque regression is common when LDL falls to about 80 or below (Medscape interview) Louis Nervegna · Jun 14, 2025 · Facebook
  33. Over a third of 'low-risk' adults had coronary plaque; low LDL and ApoB were protective Gokhan Can · Aug 18, 2024 · Facebook
  34. Circulating oxidized LDL tests do not predict CVD risk once ApoB is accounted for Louis Nervegna · Sep 12, 2024 · Facebook
  35. Circulating oxidized LDL is a poor test; measure ApoB instead, says Dayspring Louis Nervegna · Feb 04, 2024 · Facebook
  36. Evolving LDL-C management (JAHA 2023): risk categories, thresholds and treatment goals Gokhan Can · Nov 25, 2023 · Facebook
  37. LDL targets by risk: below 55 for very high risk down to below 116 for low risk Louis Nervegna · May 21, 2025 · Facebook
  38. Four blood tests for hidden metabolic and heart risk: HOMA-IR, A1C, Lp(a) and ApoB Gokhan Can · Jan 01, 2026 · Facebook
  39. NLA consensus: apoB testing helps when LDL-C and risk are discordant Gokhan Can · Oct 15, 2024 · Facebook
  40. NLA consensus clarifies when to measure ApoB and matching LDL-C thresholds Louis Nervegna · Dec 13, 2025 · Facebook
  41. Personal labs on tirzepatide/retatrutide and 5 mg rosuvastatin: LDL 61, ApoB 58, eGFR 86 Gokhan Can · Oct 08, 2024 · Facebook
  42. Most of a statin's LDL lowering comes from low doses; cut the dose rather than quit Louis Nervegna · Jan 24, 2025 · Facebook
  43. Statin dose-response: most LDL lowering comes from the lowest dose (Dayspring slide) Louis Nervegna · Jun 15, 2025 · Facebook
  44. Ezetimibe lowers LDL-C about 18-20% alone and a further 21-30% on top of a statin Gokhan Can · Sep 24, 2025 · Facebook
  45. Psyllium lowers LDL 13 mg/dL and fasting glucose 37 mg/dL in type 2 diabetes Louis Nervegna · Jun 15, 2026 · Facebook
  46. Psyllium at about 10 g/day lowers LDL by roughly 13 mg/dL across 28 randomized trials Louis Nervegna · Jun 04, 2026 · Facebook
  47. 74 RCTs show oats lower LDL, blood sugar, weight and waist circumference Louis Nervegna · Jun 24, 2025 · Facebook
  48. Coconut oil raises LDL and ApoB, long-term outcomes unknown; MCT oil is a cleaner option Louis Nervegna · Oct 16, 2025 · Facebook
  49. Full-fat yogurt lowered ApoB 4 mg/dL while butter raised it 10 mg/dL in a crossover trial Louis Nervegna · Jan 19, 2026 · Facebook
  50. Louis: forcing LDL-C below 20 in low-risk people is unwise, per Willett on brain bleeds Louis Nervegna · Mar 30, 2024 · Facebook
  51. Best of the group: an index of key posts on LDL, risk and plaque reversal Gokhan Can · Mar 23, 2024 · Facebook
  52. Keto-CTA: metabolic health and large LDL particles gave no protection from plaque Louis Nervegna · Aug 18, 2025 · Facebook
  53. Keto-CTA: high LDL with good metabolic health still saw 3.8x faster plaque progression Louis Nervegna · Aug 21, 2025 · Facebook
  54. Why LMHR happens: starvation-like physiology in very lean people on keto raises LDL Louis Nervegna · Jul 23, 2024 · Facebook
  55. Some with high LDL avoid plaque, but heart disease is multifactorial and most aren't lucky Louis Nervegna · Jun 19, 2026 · Facebook
  56. High HDL tracks with lower risk in UK Biobank, but HDL-raising drugs have failed Louis Nervegna · Oct 28, 2026 · Facebook
  57. Lipoprotein(a) explained: 80-90% genetic, stable for life, a risk factor beyond LDL Gokhan Can · Oct 05, 2024 · Facebook
  58. Standard cholesterol tests miss Lp(a), remnant and ApoB-rich particles Louis Nervegna · Dec 03, 2025 · Facebook

Keep exploring

Related research summaries

Topics and hashtags in this summary